ANI Pharmaceuticals' (ANIP) shares were nearly 1% lower Monday after the drug maker said it has completed its acquisition of Alimera Sciences (ALIM).

ANI Pharmaceuticals said it continues to expect the transaction to drive high single-digit to low double-digit accretion in its adjusted non-GAAP earnings per share in 2025 with "substantially higher accretion thereafter."

The deal also should deliver an extra $35 million to $38 million in adjusted non-GAAP earnings before interest, taxes, depreciation and amortization in 2025, including around $10 million in expected cost synergies, the company said.

Price: 57.93, Change: -0.58, Percent Change: -0.99